Silent Carriers Keep Candida Auris Moving Through U.S. Hospitals

6,197 clinical Candida auris cases were reported in the United States in 2024, more than double the 2,882 cases logged in 2022. Provisional weekly tallies show the climb has not stopped. Through the week ending September 26, 2026, states had already reported 5,661 clinical cases, compared with 5,014 at the same point in 2025.

The patients filling those counts are often not the ones seeding the next ward. Colonized people can carry the yeast on skin for months with no symptoms, then take it into the next hospital or nursing home that admits them.

Clinical Cases More Than Doubled From 2022 to 2024

A CDC surveillance summary covering 2022 through 2024, led by physician Jeremy A.W. Gold of the Mycotic Diseases Branch, found that clinical cases rose from 2,882 to 6,197 across those three years, a combined 13,507. The yearly jump slowed from 53.7 percent (2022 to 2023) to 39.9 percent (2023 to 2024), but the absolute count kept rising.

Screening detections ran far ahead of clinical illness. Facilities reported 6,226 colonization cases in 2022, 9,195 in 2023, and 12,432 in 2024, a three-year total of 27,853. That is more than twice the clinical caseload in the same window. Gold’s team cautioned that the figures describe reported cases, not population incidence, because testing and screening practices changed by year and by state.

CLINICAL CASES VERSUS COLONIZATION SCREENS

Clinical cases have been nationally notifiable since 2019. Screening cases joined that list in 2023, which itself can lift counts as more labs look. The first U.S. cases were reported in 2016, when about 50 clinical infections were identified. By 2021 the annual clinical total was about 1,500, after a 95.9 percent rise from 2020. In 2018, the year CDC used for its 2019 threat ranking, there were 323 clinical cases. CDC placed drug-resistant C. auris in its urgent tier, the highest of three, alongside carbapenem-resistant Acinetobacter and C. difficile.

The Patients Who Never Look Sick

CDC describes colonization as C. auris on skin or other body sites without symptoms. Those patients shed the yeast onto bed rails, doorknobs, and blood-pressure cuffs, and they remain able to spread it the entire time it stays on them. Healthy visitors and staff without the usual risk factors rarely pick up infection. The reservoir is the already sick.

Anna D. Baker, a CDC epidemiologist, and colleagues reviewed 21,195 U.S. patients with a positive colonization screen from 2016 through 2023. In that group, 6.9 percent later had a clinical specimen (1,458 people). Blood was involved in 2.8 percent of everyone screened. Median time from the first positive screen to the first clinical specimen was 46 days, and 58 days when the later specimen was blood. Progression was highest when the screen was collected in a long-term acute care hospital, at 10.4 percent (907 of 8,716).

COLONIZATION IN NUMBERS

• Later illness: 6.9 percent of 21,195 colonized patients went on to a clinical specimen, including 2.8 percent with blood.
• Staff contact: In a 109-patient multicenter study led by L.M. O’Hara, the yeast was found on gloves or gowns after 29 percent of 1,083 care interactions.
• Time lag: Median 46 days from a positive screen to a clinical specimen, long enough for several facility transfers.

CDC does not recommend antifungal drugs for colonization, or for yeast found only in urine or the respiratory tract without signs of infection. There is also no recommended decolonization protocol. Baker’s paper said strategies to prevent invasive disease among colonized patients, including decolonization, still need to be built. Until then, a person who feels well can leave one facility, ride in an ambulance, and open a new cluster in the next building.

Why Screening Maps and Outbreak Maps Diverge

Among screening cases with a known facility type, the share collected in acute care hospitals rose from 24.7 percent in 2022 to 50.7 percent in 2024, while the long-term acute care hospital share fell from 56.1 percent to 35.7 percent. Gold’s group wrote that the shift may reflect more admission screening in hospitals, not a sudden change in where the yeast lives.

Blood as a share of clinical specimens fell from 34.4 percent in 2022 to 25.6 percent in 2024. Urine was the most common clinical specimen overall at 31.5 percent, with blood at 30.2 percent. Isolating Candida from blood usually means invasive infection. A urine isolate may be infection or colonization found during ordinary testing, depending on how the lab works. Expanded species identification of non-blood yeasts can add clinical cases without adding bloodstream disease.

Public discussion still flattens those distinctions. Mid-2026 headlines treated a few thousand screening detections as a nationwide infection wave, and replies mixed the hospital yeast with ordinary thrush. The useful split is the one CDC already draws. A positive skin swab is not a bloodstream infection, and it is also not harmless, because the same person still sheds onto the next shared cuff.

Through the week ending September 26, 2026, California had 1,233 clinical cases year to date (964 a year earlier) and Nevada 779 (600). Texas was third at 601, slightly below its 628 at the same point in 2025. At least 28 states had reported clinical cases as of September 5. Some states still do not report the condition the same way, so the map of “who has C. auris” is also a map of who looks.

Common Hospital Cleaners Miss This Yeast

C. auris survives on surfaces for weeks and, CDC says, can persist for many months. It has been cultured from bedside tables and bed rails and from windowsills farther from the patient. Shared gear that moves ward to ward (glucometers, temperature probes, blood-pressure cuffs, ultrasound machines, ventilators) can carry it if it is not cleaned after each use.

Several everyday hospital products fail. CDC says products that rely only on quaternary ammonia compounds do not work against this yeast, and some products labeled for Candida albicans or as fungicidal still miss C. auris. The agency tells facilities to use an EPA-registered hospital disinfectant with a C. auris claim and points them to the List P of registered surface disinfectants. Ultraviolet devices and vaporized hydrogen peroxide are, for now, a supplement to wiping, not a replacement. CDC says the settings needed for those machines to kill C. auris are not well worked out.

WHERE CONTAINMENT BREAKS

• The cleaner: Quat-only products, and some general fungicides, leave the yeast on rails and cuffs.
• The handoff: Colonized patients keep moving; CDC wants C. auris status flagged on transfer and readmission, not only on the isolation door.
• The drug: Colonization is not treated, and no decolonization method is recommended, so skin carriage can outlast a hospital stay.
• The room: Shared rooms need three feet between beds, curtain barriers, and mop heads and cloths changed between bed areas, rules that slip when staffing is tight.

Alcohol-based hand sanitizer is preferred when hands are not visibly dirty. Gloves do not replace that step. In nursing homes, CDC allows Contact Precautions or Enhanced Barrier Precautions, which is a different package than the Contact Precautions used in acute care and long-term acute care hospitals. Facilities that already handle other multidrug-resistant organisms can, in principle, handle C. auris. The gap is doing the work every shift, including on environmental services and on the people who roll shared carts.

Most Clinical Cases Are in People 45 and Older

Among clinical cases with age reported, 87.8 percent were in adults 45 or older. Men accounted for 61.0 percent. Screening cases were similar: 90.0 percent were 45 or older, and 57.9 percent were male. Only 21 clinical cases in 2022-2024 (0.2 percent) were in people 17 or younger.

Most clinical specimens were collected in acute care hospitals (76.6 percent) and long-term acute care hospitals (17.8 percent). Risk, as CDC lists it, is prolonged facility stays, invasive devices (breathing tubes, feeding tubes, venous catheters, urinary catheters), and recent antimicrobial drugs. Peter Chin-Hong, an infectious disease doctor at the University of California, San Francisco, said the risk is not for everyday people in the community but is concentrated in healthcare settings.

When patients with C. auris die, CDC notes it is hard to say how much the yeast added on top of the illnesses that put them in those beds. For invasive disease, Gold’s summary cites crude mortality in the 30 percent to 72 percent range. That spread is wide because the denominator is already frail. Bloodstream infection is still the outcome infection-control teams are trying to prevent when they swab armpits and groins on admission.

Echinocandins Still Work, Until They Don’t

Most U.S. isolates resist fluconazole, a workhorse azole. CDC’s Antimicrobial Resistance Laboratory Network, in testing described for 2022-2023, found about 95 percent of clinical isolates fluconazole resistant, 15 percent resistant to amphotericin B, and 1 percent resistant to echinocandins. Echinocandins remain the first treatment CDC recommends for adults and for children older than 2 months. Infants under 2 months are started on amphotericin B deoxycholate.

Echinocandin-resistant and pan-resistant strains (resistant to azoles, echinocandins, and polyenes) have already been found in the United States. CDC says those reports are increasing, and some outbreaks have involved people who shared healthcare exposure without prior antifungal treatment, which points to person-to-person spread of already resistant strains. For those infections, clinicians may combine drugs or try a newer antifungal. The bench is still short. Antifungal programs have long drawn less money than antibacterial ones, because fungal cells are closer to human cells and because the paying market is smaller.

The rapid emergence around the world and the speed of spread in the U.S. is alarming

Susan Huang, infectious disease researcher, University of California, Irvine School of Medicine

That speed is what the 2019 urgent label was meant to flag, when the country had 323 clinical cases. The 2024 total of 6,197 is the same organism, in the same kinds of rooms, with the same first-line drug class still holding for most patients and failing for a growing few.

The Transfer Sheet That Hospitals Still Skip

Gold’s public-health action list is blunt: transmission-based precautions, disinfection with products that actually kill C. auris, and communication of C. auris status when a patient moves. CDC’s infection-control guidance says that status should be communicated during patient transfer and discharge, and that the chart should be flagged for readmission. Patients are told to inform the next provider about a prior infection or a positive screen. Colonization can continue after an infection has been treated, so a “cleared” discharge is not a cleared skin.

THE DECADE SINCE THE FIRST U.S. CASE

1. 2016: First U.S. clinical cases reported, about 50 that year, many tied at first to healthcare abroad.
2. 2019: CDC lists drug-resistant C. auris as an urgent antimicrobial-resistance threat; clinical cases become nationally notifiable; 323 clinical cases had been counted in 2018.
3. 2023: Screening cases become nationally notifiable; clinical cases reach 4,428.
4. 2024: Clinical cases reach 6,197 and screening cases 12,432.
5. September 26, 2026: National Notifiable Diseases Surveillance System weekly tables show 5,661 clinical cases year to date, with California, Nevada, and Texas still the volume leaders.

The hidden stakeholder in those dates is not a new superbug headline. It is the colonized resident on a ventilator in long-term care, the nurse whose gown picked up yeast on 29 percent of contacts in O’Hara’s cohort, and the receiving hospital that never got the fax. Until screening, List P cleaning, and transfer flags run as one circuit, the next clinical case will keep arriving with the gurney.

Disclaimer: This article is news reporting and analysis of public CDC surveillance and infection-control guidance. It is informational only and is not medical advice, a diagnosis, or a treatment plan for Candida auris or any other infection. Readers who have questions about symptoms, screening, isolation, or antifungal drugs should speak with a licensed physician or infection-disease specialist who can review their own records. Case counts, resistance rates, and recommended products reflect the CDC, NNDSS, and EPA sources cited here and can change as later weekly tables and lab results are updated.